U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07767513) titled 'Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events' on Aug. 12.
Brief Summary: This study is designed to evaluate the efficacy and safety of HRS-5346 Tablets in participants with high cardiovascular event risk and elevated Lp(a), and to investigate the appropriate dosage of HRS-5346 Tablets
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Lipoprotein Disorder
Intervention:
DRUG: HRS-5346
HRS-5346; Dose1
DRUG: HRS-5346
HRS-5346; Dose2
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shandong Suncadia Medicine Co., Ltd.
Disclaimer: Curated by HT Sy...